-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
First Public Notice of the Environmental Impact Assessment for the Green Development Project of Active Pharmaceutical Ingredients by Shisi Pharmaceutical Group Hebei Guolong Pharmaceutical Co., Ltd.
Category:
Time：2021-08-27
According to the “Measures for Public Participation in Environmental Impact Assessment” (Ministry Order No. 4, July 16, 2018), the project proponent shall, within 7 working days after determining the entity responsible for preparing the environmental impact report, disclose relevant information via an online platform.
I. Basic Information on the Project
1. Project Name: Green Development Project for Active Pharmaceutical Ingredients of Hebei Guolong Pharmaceutical Co., Ltd., Shisi Pharmaceutical Group
2. Construction Address: South of Sanxia Road and west of Gongye Avenue, Shijiazhuang Economic and Technological Development Zone
3. Construction Content: The project will build a new workshop with a floor area of approximately 3,750 square meters, along with production lines for 11 pharmaceutical products—including tenofovir disoproxil fumarate and linezolid—and associated logistics facilities and supporting power infrastructure.
4. Construction Scale: The annual production capacity will be 16 tons/year for tenofovir disoproxil fumarate and linezolid combined, and a total of 2.43 tons/year for the other nine varieties.
II. Name and Contact Information of the Construction Entity
Construction Unit Name: Hebei Guolong Pharmaceutical Co., Ltd.
Contact: Wei Xiaowei
Phone number: 18032935650
3. Name of the organization preparing the Environmental Impact Report
Hebei Jidu Environmental Protection Technology Co., Ltd.
IV. Web Link to the Public Opinion Form
The public can download the public opinion form and submit their feedback by visiting the following link starting from the date of this announcement: https://pan.baidu.com/s/1ohxnwAYjmpD9ascQ1V_oMw (Extract code: n69n).
V. Ways and channels for the public to submit comments
The public can contact the construction entity via letter, fax, email, telephone, and other similar means.
Construction Unit Name: Hebei Guolong Pharmaceutical Co., Ltd.
Contact: Wei Xiaowei
Phone number: 18032935650
Fax: 0311-67107152
Email: 821736359@qq.com
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license